(A version of this story originally appeared at Marijuana Business Daily and will be updated.) An Irish pharmaceutical firm, Jazz Pharmaceuticals, has agreed to purchase United Kingdom-based GW Pharmaceuticals, one of the largest medical cannabinoid companies in the world, for $7.2 billion, the drug companies said Wednesday. The proposed cash-and-stock deal would be the largest
Epidiolex
This story first appeared at Marijuana Business Daily International. United Kingdom-based GW Pharmaceuticals expects to report annual sales of approximately $526 million for the year ended Dec. 31, 2020, it said in a preview of its fourth quarter and full-year results. Fourth-quarter net sales will be approximately $148 million, based on preliminary unaudited financial information,
A longer version of this story appears at Marijuana Business Daily International. Sales of medical marijuana in Denmark posted healthy gains in the third quarter of 2020, coinciding with the launch of GW Pharmaceuticals’ CBD drug Epidiolex. Overall sales of all medial cannabis products grew from about 13 million Danish Krones ($2 million) in the
